Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics

dc.contributor.author
Martínez-Clemente, José
dc.contributor.author
López Arnau, Raúl
dc.contributor.author
Carbó Banús, Marcel·lí
dc.contributor.author
Pubill Sánchez, David
dc.contributor.author
Camarasa García, Jordi
dc.contributor.author
Escubedo Rafa, Elena
dc.date.issued
2014-05-13T10:56:02Z
dc.date.issued
2014-05-13T10:56:02Z
dc.date.issued
2013-05-07
dc.date.issued
2014-05-13T10:56:02Z
dc.identifier
0033-3158
dc.identifier
https://hdl.handle.net/2445/53992
dc.identifier
622132
dc.description.abstract
Fe d'errates disponible a: http://​dx.​doi.​org/​10.​1007/​s00213-013-3283-6
dc.description.abstract
Rationale Mephedrone (4-methylmethcathinone) is a still poorly known drug of abuse, alternative to ecstasy or cocaine. Objective The major aims were to investigate the pharmacokineticsa and locomotor activity of mephedrone in rats and provide a pharmacokinetic/pharmacodynamic model. Methods Mephedrone was administered to male Sprague-Dawley rats intravenously (10 mg/kg) and orally (30 and 60 mg/kg). Plasma concentrations and metabolites were characterized using LC/MS and LC-MS/MS fragmentation patterns. Locomotor activity was monitored for 180-240 min. Results Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α=10.23 h−1, β=1.86 h−1). After oral administration, peak mephedrone concentrations were achieved between 0.5 and 1 h and declined to undetectable levels at 9 h. The absolute bioavailability of mephedrone was about 10 % and the percentage of mephedrone protein binding was 21.59±3.67%. We have identified five phase I metabolites in rat blood after oral administration. The relationship between brain levels and free plasma concentration was 1.85±0.08. Mephedrone induced a dose-dependent increase in locomotor activity, which lasted up to 2 h. The pharmacokinetic-pharmacodynamic model successfully describes the relationship between mephedrone plasma concentrations and its psychostimulant effect. Conclusions We suggest a very important first-pass effect for mephedrone after oral administration and an easy access to the central nervous system. The model described might be useful in the estimation and prediction of the onset, magnitude,and time course of mephedrone pharmacodynamics as well as to design new animal models of mephedrone addiction and toxicity.
dc.format
12 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Springer Verlag
dc.relation
Versió postprint del document publicat a: http://dx.doi.org/10.1007/s00213-013-3108-7
dc.relation
Psychopharmacology, 2013, vol. 229, num. 2, p. 295-306
dc.relation
http://dx.doi.org/10.1007/s00213-013-3108-7
dc.relation
http://​dx.​doi.​org/​10.​1007/​s00213-013-3283-6
dc.rights
(c) Springer Verlag, 2013
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject
Amfetamines
dc.subject
Sistema nerviós central
dc.subject
Cervell
dc.subject
Farmacocinètica
dc.subject
Efectes fisiològics
dc.subject
Drogues de disseny
dc.subject
Amphetamines
dc.subject
Central nervous system
dc.subject
Brain
dc.subject
Pharmacokinetics
dc.subject
Physiological effect
dc.subject
Designer drugs
dc.title
Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/acceptedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)